When only ER+ or unknown patients were included, the corresponding improvements in these endpoints was 25% (HR = 0.75; P = 0.0001), 18% (HR = 0.82; P = 0.03), and 17% (HR = 0.83; P = 0.05), with the latter OS endpoint being marginally significant (Coombes et al. 2007 ).
← all excerpts
Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.
1
—
—